Overview

A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Collaborators:

Genentech, Inc.
Tanox

Treatments:

Antibodies
Immunoglobulin E
Immunoglobulins
Omalizumab